Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study

Esposito, Antonietta; Valentino, Maria Rosaria; Bruzzese, Dario; Bocchino, Marialuisa; Ponticiello, A; Stanziola, Anna Agnese; Sanduzzi, Alessandro

doi:10.1016/j.pupt.2016.03.003

Cited by 8 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were obtained in the studies carried out by Tatsumi et al and Yasuda et al including COPD patients treated with carbocysteine 1,500 mg daily during one year [28,29]. In addition, results of the study carried out by Esposito et al suggested that daily administration of carbocysteine for prolonged period in addition to regular COPD treatment could be considered as a good strategy for reduction of exacerbation frequency [30]. Furthermore, results from several studies indicated that carbocysteine could restore steroid sensitivity in steroid insensitive pulmonary diseases and could improve the targets of regular treatment in patients with severe COPD [31,32].…”

Section: Discussionsupporting

confidence: 80%

Carbocysteine in the Management of Stable COPD: Are Its Antioxidant and Anti-Inflammatory Properties Clinically Relevant?

Минов

Karadžinska-Bislimovska

Petrova

et al. 2017

SEE J Immunol

View full text Add to dashboard Cite

BACKGROUND: The recent epidemiological and experimental evidence suggest possible antioxidant effect of carbocysteine in patients with chronic obstructive pulmonary disease (COPD).AIM: To assess efficacy and tolerability of carbocysteine in the management of stable COPD.METHODS: We performed an observational, non-randomized, open study (a real life study) including 87 patients with stable COPD (group B and D by combined COPD assessment) divided in two groups, examined group (EG) and control group (CG). All participants were treated with the regular treatment of the stable disease, but in the participants of the EG carbocysteine 1,500 mg daily was added to their regular treatment during the period of two months. The study protocol included completion of the COPD Assessment Test (CAT) and spirometric measurements at initial visit and at the end of the mentioned period.RESULTS: We found significantly lower mean value of the overall CAT score in the EG at the end of the study as compared to its mean value registered at initial visit (26.9 vs. 24.3; P = 0.007). In regard to certain CAT items, we found significantly lower values of the mean scores related to cough phlegm and sleep disturbances as compared to their mean scores at initial visit. In addition, the mean values of the overall CAT scores at initial visit and at the end of the study in controls were similar. In EG we found significantly higher mean value of the MEF 25-75 at the end of the study as compared to its mean value registered at initial visit (59.3% vs. 67.2%; P = 0.003). There was no significant difference in the mean values of other spirometric parameters at the end of the study as compared to their mean values at initial visit. In controls we registered similar values of all measured spirometric parameters at the end of the study as compared to their values registered at initial visit. Mild gastrointestinal manifestations were registered in 13.3% of the participants of the EG during the examined period.CONCLUSION: Our findings indicate positive effects of carbocysteine regarding the symptoms and lung function, as well as its good tolerability in the patients with stable COPD

show abstract

Section: Discussionsupporting

confidence: 80%

Carbocysteine in the Management of Stable COPD: Are Its Antioxidant and Anti-Inflammatory Properties Clinically Relevant?

Минов

Karadžinska-Bislimovska

Petrova

et al. 2017

SEE J Immunol

View full text Add to dashboard Cite

show abstract

“…These findings add new information to different studies that demonstrated the efficacy of carbocysteine to reduce the exacerbation rate in asthmatics or COPD patients [6,7,26], while not explaining the molecular mechanisms that might underline this clinical efficacy.…”

Section: Discussionmentioning

confidence: 65%

“…Carbocysteine is one of the most used mucolytic drug with anti-inflammatory and antioxidant action [6,7]. There is limited evidence demonstrating the in vivo anti-inflammatory or antioxidant activities of carbocysteine in COPD or asthmatic patients.…”

Section: Discussionmentioning

confidence: 99%

“…Several clinical studies demonstrated that the use of mucolytic agents associated with traditional therapy could reduce the frequency of exacerbations, and they represents a costeffective therapy in patients who exacerbate frequently and produce sputum chronically [5]. Carbocysteine, one of the used mucolytic drugs, has anti-inflammatory and antioxidant actions [6,7]. However, there is a limited number of studies that analyze the efficacy of carbocysteine in specific phenotypes of patients or study the molecular mechanisms underlying its efficacy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Carbocysteine Modifies Circulating miR-21, IL-8, sRAGE, and fAGEs Levels in Mild Acute Exacerbated COPD Patients: A Pilot Study

et al. 2022

View full text Add to dashboard Cite

Patients with Chronic Obstructive Pulmonary Disease (COPD) periodically experience acute exacerbation (AECOPD). Carbocysteine represents a valid add on therapy in COPD by exerting antioxidant and anti-inflammatory activities. The in vivo effects of carbocysteine on inflammatory markers are not yet fully understood. The aims of this study were to assess: (i) miR-21, IL-8, soluble Receptor for Advanced Glycation End Products (sRAGE), and fluorescent Advanced Glycation End Products (fAGEs) in control subjects (n = 9), stable (n = 9), and AECOPD patients (n = 24); and (ii) whether carbocysteine modifies these markers and the functional parameters in mild AECOPD patients. Mild AECOPD patients received or not carbocysteine along with background inhalation therapy for 20 days. At the onset and at the end of the observation period, the following parameters were evaluated: FEV1, FEF25–75%, CAT questionnaire; miR-21 by Real Time PCR; IL-8 and sRAGE by ELISA; and fAGEs by spectro-fluorescence method. COPD patients showed higher levels of miR-21, IL-8, fAGEs and lower levels of sRAGE compared to that of controls. miR-21 inversely correlated with FEV1. IL-8 and fAGEs were significantly different in stable and exacerbated COPD patients. Carbocysteine improved symptoms, FEV1 and FEF25–75%, increased sRAGE, and reduced miR-21, IL-8, and fAGEs in mild AECOPD patients. The present study provides compelling evidence that carbocysteine may help to manage mild AECOPD by downregulating some parameters of systemic inflammation.

show abstract

“…7 Carbocisteine (S-carboxymethylcysteine), prepared by alkylation of cysteine using chloroacetic acid, improves the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis. 8 New methods and procedures were developed to synthesize organic sulfides. For this purpose, metal-catalyzed reactions, [9][10][11] Sandmeyer and Leuckart reactions, 12,13 coupling of thiols with Grignard reagents in the presence of N-chlorosuccinimide, 14 photocatalytically initiated thiol-ene reaction, 15 free radical displacement on alkynes, 16 regioselective conjugate addition of thiols to acyclic α,β,γ,δ-unsaturated dienones, 17 in situ nucleophilic substitution of aryl bromides with potassium iodomethyltrifluoroborates, 18 displacement reaction of halogens by sulfur, 19 Stevens rearrangement of thioethers with arynes, 20 and synthesis of thiiranes via reaction of epoxides with thiourea in DES 21 were proposed by researchers.…”

Section: Introductionmentioning

confidence: 99%

Multicomponent Solvent-Free Synthesis, Antibacterial Evaluation and QSAR Study of 2-(Bis(benzylthio)methylene) malononitriles

Beyzaei

Baranipour

Aryan

et al. 2018

ACSi

View full text Add to dashboard Cite

Multicomponent reaction of malononitrile, carbon disulphide and various benzyl halides was developed as an efficient strategy for the synthesis of 2-(bis(benzylthio)methylene)malononitrile derivatives via two different procedures: (a) in the presence of K 2 CO 3 as a base in acetonitrile and (b) under solvent-free conditions in the presence of triethylamine. Higher yields with shorter reaction times were obtained from the latter procedure. Inhibitory activity of all derivatives was evaluated against 22 pathogenic bacteria including both Gram-negative and Gram-positive strains. Thioether 4b showed broad-spectrum antibacterial activities according to the antibiogram tests. DFT calculations (B3LYP/6-311++G**) were performed to determine the type of drug-receptor interactions. It was found that reversible dipole-dipole forces play a key role in most interactions.

show abstract

Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study

Cited by 8 publications

References 15 publications

Carbocysteine in the Management of Stable COPD: Are Its Antioxidant and Anti-Inflammatory Properties Clinically Relevant?

Carbocysteine in the Management of Stable COPD: Are Its Antioxidant and Anti-Inflammatory Properties Clinically Relevant?

Carbocysteine Modifies Circulating miR-21, IL-8, sRAGE, and fAGEs Levels in Mild Acute Exacerbated COPD Patients: A Pilot Study

Multicomponent Solvent-Free Synthesis, Antibacterial Evaluation and QSAR Study of 2-(Bis(benzylthio)methylene) malononitriles

Contact Info

Product

Resources

About